Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
Rachel G WoodfordDeborah Di-Xin ZhouPeey Sei KokSally J LordMichael L FriedlanderIan C MarschnerR John SimesChee Khoon LeePublished in: JCO precision oncology (2024)
PFS-2 offers improved correlation with OS than PFS with a modest increase in follow-up time and sample size. PFS-2 should be considered as a primary end point in future trials of advanced cancers.